The purpose of this study is to determine whether active stimulation of the affected hemisphere will be more effective than simulated current in treatment of stroke
Stroke is defined as an acute neurological dysfunction of vascular origin, with subtle development of clinical signs of cerebral function disturbs, lasting more than 24h. The traditional therapy includes drugs and physical rehabilitation, without systematization, with complicates its replication. The transcranial direct current (DC) stimulation might promote an increase in the motor function of the hands, when compared with placebo stimulation. In fact, some clinical trials point positive effects of transcranial DC stimulation (tDCS) as a post-stroke intervention, however, in general, they only include patients in the chronic stage, with cerebral damage in different areas and diverse disabilities, most being assisted by non-standardized physical therapy treatments. tDCS combined with a standardized physiotherapy program, noted as constraint-induced movement therapy (CIMT), could be able to modulate the cortical excitability and promote better functional recovery. However, no relate of longitudinal studies assessing patients in the acute stage submitted to tDCS and physiotherapy for more than 6 months have been found. Studies like this would help us elucidate the action mechanisms of this treatment in the early stages of stroke. With this in mind, START - tDCS, a phase II/III clinical trial, will be developed to assess the therapeutic effects of the tDCS in early stage enrolling 40 post-stroke patients. They will be allocated in 2 groups at random to receive active tDCS or sham, associate to CIMT. The protocol will be applied in a daily basis for 10 consecutive working days (2 weeks), after that, the patients will be followed for 1 month. By the end of the study, the participants that receive tDCS and show better clinical condition will be invited to participate in bimonthly stimulation for 12 months, as part of a longitudinal study regarding tDCS for stroke. An increase in the clinical condition will be considered as a final score higher than 10 points in the Barthel Index, our primary outcome, when compared with baseline, before the treatment protocol.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Enrollment
40
Federal University of Paraíba,Department of Psychology
João Pessoa, Paraíba, Brazil
Functional Independence measured by Barthel Index
Time frame: Change for functional independence at 4 months
Cognitive dysfunction (Montreal Cognitive Assessment)
Time frame: Baseline (week 1) and Endpoint (week 4)
Executive functions (Victoria version of the Stroop Color and Word Test)
Time frame: Baseline (week 1) and Endpoint (week 4)
Attention and Working Memory (Digit span subtest)
Time frame: Baseline (week 1) and Endpoint (week 4)
Spasticity
Time frame: Baseline, Week 2 and Week 4
Muscle strength
Time frame: Baseline, Week 2 and Week 4
Balance
Time frame: Baseline, Week 2 and Week 4
Posture
Time frame: Baseline, Week 2 and Week 4
Fear of falling during daily life activities
Time frame: Baseline, Week 2 and Week 4
Upper limb function
Time frame: Baseline, Week 2 and Week 4
Quality of life
Time frame: Baseline, Week 2 and Week 4
Lower limb function
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Time frame: Baseline, Week 2 and Week 4